Transcutaneous Electrical Acustimulation (TEA) for Gastroparesis

University of Michigan logo

University of Michigan

Status

Enrolling

Conditions

Gastroparesis With Diabetes Mellitus

Treatments

Device: transcutaneous electrical accustimulation at treatment point.
Device: transcutaneous electrical accustimulation at sham point.

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT05362578
1R44AT011380-01A1 (U.S. NIH Grant/Contract)
HUM00204800

Details and patient eligibility

About

The device being studied, the Transcutaneous Electrical Accustimulator (TEA), will deliver weak electrical current at two specific points, one at the leg and the other at the arm at settings known to improve symptoms involving the digestive system. The study team would like to test if the device will impact the gastrointestinal (GI) symptoms and gastric motility in study participants with gastroparesis.

Full description

This study aims to assess if the device will impact the (GI) symptoms and gastric motility in study participants with gastroparesis. This will be done over a 12 week period during which each participant will undergo two visits. Each visit will take place over two days and both visits will follow the same schedule. During the first day, subjects will undergo a gastric emptying breath test which will be used to measure stomach emptying, which will last approximately 5 hours. During the second day, subjects will undergo a 3-in-1 gastric functional test which is a non-invasive method to assess the gastric motility and visceral pain. This test will entail an EGG, ECG, and nutrient drink test for gastric accommodation. Following the 3-in-1 gastric functional test, subjects will be randomized and trained on how to use the smartphone and the study device. Half of the patients will be assigned to the sham group and half will be assigned to the treatment group. Each group will undergo 8 weeks of treatment or 8 weeks of sham stimulation and will receive weekly calls from the study team to check for adverse events and study compliance. Following the first 8 week period, subjects will return to the study site to undergo visit two. This will follow the same two-day format as visit 1. At this time, subjects will become unblinded. Those who received sham stimulation will be trained on the correct locations for each TEA device and will receive 4 weeks of treatment with the device.

Enrollment

60 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • At least a 3-month history of diabetic gastroparesis symptoms on an on-going basis; at least one severe gastroparetic symptom or two moderate gastroparetic symptoms (e.g. vomiting, nausea, early satiety, bloating, or epigastric or abdominal pain) during the screening.
  • Documented delayed gastric emptying within past 3 years
  • Stable concomitant medications, defined as no changes in regimen for at least 2 weeks prior to the experiment (daily adjustments of insulin doses are permitted if patient has diabetes)

Exclusion criteria

  • Currently receiving parenteral feeding or presence of a nasogastric or other enteral tube
  • History of gastric surgery such as fundoplication, gastrectomy, or vagotomy
  • Symptoms suggestive of gastroparesis with no diagnosis of diabetes
  • Pregnancy or expect to conceive during the course of the study
  • Uncontrolled diabetes mellitus (HbA1c > 11%).
  • Having any implanted medical device, such as cardiac pacemaker or Entera device

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

60 participants in 2 patient groups

Treatment group
Experimental group
Description:
Subjects will be trained to use the devices at the treatment points and will undergo the treatment twice per day for 8 weeks. Following the first 8 weeks, at visit two, the devices will be collected by the study team.
Treatment:
Device: transcutaneous electrical accustimulation at treatment point.
Sham group
Sham Comparator group
Description:
Subjects will be trained to use the devices at sham points and will undergo sham stimulation for the first 8 weeks. At visit two, after unmasking, subjects will optionally be trained on the treatment points and may participate in treatment for 4 weeks.
Treatment:
Device: transcutaneous electrical accustimulation at sham point.

Trial contacts and locations

1

Loading...

Central trial contact

Colin Burnett

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems